In addition, activation of the PI3K-Akt pathway in tumors with PTEN deletion has been shown to be associated with repressed androgen signalling in prostate cancer, while suppression of the PI3K-Akt pathway was demonstrated to activate androgen receptor signalling [71,72]. This evidence concerns the gene AKT1 and prostate carcinoma.